Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

Leukemia

Volumn 27, Issue 4, 2013, Pages 947-953

  Kastritis, E ^a   Terpos, E ^a   Moulopoulos, L ^a   Spyropoulou Vlachou, M ^a   Kanellias, N ^a   Eleftherakis Papaiakovou, E ^a   Gkotzamanidou, M ^a   Migkou, M ^a   Gavriatopoulou, M ^a   Roussou, M ^a   Tasidou, A ^b   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

bone marrow; free light chains; immunoparesis; risk; smoldering myeloma; trephine biopsy

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADULT; AGED; ANEMIA; ARTICLE; ASYMPTOMATIC MULTIPLE MYELOMA; BONE LESION; BONE MARROW CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; CELL INFILTRATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPINE;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84876115894     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.309     Document Type: Article

References (23)

1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
2. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-2590.
3. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127.
4. Blade J, Dimopoulos M, Rosinol L, Rajkumar SV, Kyle RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010; 28: 690-697.
5. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785-789.
6. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586-2592.
7. Hillengass J, Fechtner K, Weber MA, Bauerle T, Ayyaz S, Heiss C et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010; 28: 1606-1610.
8. Rosinol L, Blade J, Esteve J, Aymerich M, Rozman M, Montoto S et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003; 123: 631-636.
9. Moulopoulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995; 13: 251-256.
10. Moulopoulos LA, Dimopoulos MA, Christoulas D, Kastritis E, Anagnostou D, Koureas A et al. Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia 2010; 24: 1206-1212.
11. Moulopoulos LA, Dimopoulos MA, Kastritis E, Christoulas D, Gkotzamanidou M, Roussou M et al. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. Am J Hematol 2012; 87: 861-864.
12. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
13. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008; 113: 1588-1595.
14. Mateos M-V, Lopez-Corral L, Hernandez M, Giraldo P, De La Rubia J, de Arriba F et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on lenalidomidedexamethasone (len-dex) as induction therapy followed by maintenance therapy with len alone vs no treatment. ASH Annual Meeting Abstracts 2011; 118: 991.
15. Terpstra WE, Lokhorst HM, Blomjous F, Meuwissen OJ, Dekker AW. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol 1992; 82: 46-49.
16. Joshi R, Horncastle D, Elderfield K, Lampert I, Rahemtulla A, Naresh KN. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. J Clin Pathol 2008; 61: 213-216.
17. Stifter S, Babarovic E, Valkovic T, Seili-Bekafigo I, Stemberger C, Nacinovic A et al. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma. Diagn Pathol 2010; 5: 30.
18. Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365: 474-475.
19. Larsen JT, Kumar S, Rajkumar SV. Serum free light chain ratio in distinguishing smoldering multiple myeloma from active multiple myeloma. ASH Annual Meeting Abstracts 2011; 118: 3948.
20. D'Arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term followup of a randomized study. Leuk Lymphoma 2011; 52: 771-775.
21. Heuck C, Sexton R, Dhodapkar M, Zhang Q, Usmani S, Nair B et al. SWOG S0120 observational trial for MGUS and asymptomatic multiple myeloma (AMM): imaging predictors of progression for patients treated at UAMS. ASH Annual Meeting Abstracts 118: 3955.
22. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011; 118: 5989-5995.
23. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomographycomputed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007; 92: 50-55.